Anthony F. Shields

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Abstract CT073: FiREBOLT: A phase 1 study evaluating radioligand therapy with LY4337713 in adults with select FAP+ solid tumors (Trial in progress)

  Cancer Research · 2026-04-17

• Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib

  JAMA Oncology · 2025-12-04 · 5 citations

• Supplementary Table S4 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)

  2025-11-25

• Supplementary Table S1 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)

  2025-11-25

• Supplementary Figure S2 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)

  2025-11-25

• Supplementary Table S5 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)

  2025-11-25

• Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinomaPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-11-25

• Supplementary Table S2 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)

  2025-11-25

• Supplementary Figure S1 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)

  2025-11-25

• Supplementary Figure S3 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)

  2025-11-25

• Supplementary Methods S1 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)

  2025-11-25

• Supplementary Table S3 from Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance)

  2025-11-25

• 520 Safety and tolerability of ASP1012, an oncolytic virus, in adults with locally advanced or metastatic solid tumors: Results from a first-in-human, phase 1, open-label, dose-escalation study

  Regular and Young Investigator Award Abstracts · 2025-11-01

• Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (Alliance)

  JNCI Journal of the National Cancer Institute · 2025-09-20 · 3 citations

• Supplemental Table 2 from Characterization of Plasma Cell-Free DNA Variants as of Tumor or Clonal Hematopoiesis Origin in 16,812 Advanced Cancer PatientsPreprint

  2025-07-01

• Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors

  Scientific Reports · 2025-07-01 · 7 citations

• Data from Characterization of Plasma Cell-Free DNA Variants as of Tumor or Clonal Hematopoiesis Origin in 16,812 Advanced Cancer PatientsPreprint

  2025-07-01

• Supplemental Material 1 from Characterization of Plasma Cell-Free DNA Variants as of Tumor or Clonal Hematopoiesis Origin in 16,812 Advanced Cancer PatientsPreprint

  2025-07-01

• Abstract P4-08-25: Overall survival in patients with HR+/HER2- advanced breast cancer treated in a phase 1b trial evaluating gedatolisib in combination with palbociclib and endocrine therapy

  Clinical Cancer Research · 2025-06-13

• Association between empirical dietary inflammatory pattern (EDIP) and survival in patients with stage III colon cancer: Findings from CALGB/SWOG 80702 (Alliance).

  Journal of Clinical Oncology · 2025-06-04 · 3 citations